{"id":"epoetin-alfa-packed-rbc-transfusion","safety":{"commonSideEffects":[{"rate":"null","effect":"Thromboembolic events"},{"rate":"null","effect":"Hypertension"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Epoetin alfa is an erythropoiesis-stimulating protein that mimics the action of endogenous erythropoietin, which is a hormone that regulates red blood cell production. By binding to the erythropoietin receptor, epoetin alfa triggers a cascade of intracellular signaling events that ultimately lead to the proliferation and differentiation of erythroid progenitor cells, resulting in increased red blood cell production.","oneSentence":"Epoetin alfa stimulates erythropoiesis by binding to the erythropoietin receptor, promoting the production of red blood cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:18.139Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of anemia associated with chronic kidney disease, chemotherapy-induced anemia, and HIV-associated anemia"}]},"trialDetails":[{"nctId":"NCT00338286","phase":"PHASE3","title":"A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2006-03-02","conditions":"Breast Cancer, Neoplasm Metastasis","enrollment":2098},{"nctId":"NCT00350519","phase":"PHASE4","title":"The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery","status":"TERMINATED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-08","conditions":"Hemostasis, Surgical","enrollment":37}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"epoetin alfa + packed RBC transfusion","genericName":"epoetin alfa + packed RBC transfusion","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epoetin alfa stimulates erythropoiesis by binding to the erythropoietin receptor, promoting the production of red blood cells. Used for Treatment of anemia associated with chronic kidney disease, chemotherapy-induced anemia, and HIV-associated anemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}